Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2]. Financial Performance - For Q1 2025, the company reported a revenue of 738 million yuan, representing a year-on-year decrease of 8.59%. The net profit was 91.43 million yuan, down 9.68% year-on-year, with a gross profit margin of 52.17% [2]. Market Position - As of May 29, Cofoe Medical's stock closed at 34.01 yuan, up 2.97%, with a rolling price-to-earnings (PE) ratio of 23.55, marking a new low in 37 days. The company's total market capitalization is 7.111 billion yuan [1]. - In comparison to the medical device industry, which has an average PE of 49.64 and a median of 36.36, Cofoe Medical ranks 50th in terms of PE [1][3]. Shareholder Information - As of April 10, 2025, Cofoe Medical had 18,000 shareholders, a decrease of 428 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].
可孚医疗收盘上涨2.97%，滚动市盈率23.55倍，总市值71.11亿元